Publications by authors named "Peter Irving"

Claim this Profile
D
Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease.
Silvio Danese, Bruce E Sands, Brian G Feagan, Vipul Jairath, Remo Panaccione, Peter M Irving

Contemp Clin Trials Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age.
Adam S Faye, David T Rubin, Corey A Siegel, Millie D Long, Nabeel Khan, Peter M Irving

Inflamm Bowel Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment.
Remo Panaccione, Marc Ferrante, Iris Dotan, Julian Panés, Tadakazu Hisamatsu, Peter M Irving

Clin Gastroenterol Hepatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of PredictSURE IBD Assay in a Multinational Cohort of Patients With Inflammatory Bowel Disease.
Dahham Alsoud, Nurulamin M Noor, Lea Ann Chen, Vivian Abadom, Simon H C Anderson, Peter M Irving

United European Gastroenterol J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program.
Gary R Lichtenstein, Jessica R Allegretti, Edward V Loftus, Peter M Irving, Rupa Banerjee

Inflamm Bowel Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Utility and Cost-Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine-Induced Myelosuppression: A Genotype-First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource.
Christopher Roberts, Jaime Peters, Aleksejs Sazonvos, Neil Goodman, Mohmmed Sharip, Peter Irving

Aliment Pharmacol Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fecal loss of vedolizumab is associated with ulcerative colitis severity, lower serum vedolizumab levels, and rates of clinical response: results from the FAVOUR study.
Mark A Samaan, Georgina Cunningham, Samuel Hsiang Lim, Patrick Dawson, Sherine Hermangild Kottoor, Peter M Irving

J Crohns Colitis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid.
Andres Yarur, Peter Irving, Britta Siegmund, Marla C Dubinsky, Ashwin N Ananthakrishnan

Inflamm Bowel Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programme.
María Chaparro, Remo Panaccione, Bruce E Sands, Peter M Irving, Martina Goetsch

BMJ Open Gastroenterol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Bruce E Sands, Geert D'Haens, David B Clemow, Peter M Irving, Jordan T Johns

Inflamm Bowel Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory Bowel Disease Advice Lines: A Scoping Review.
Naomi Hare, Christine Norton, Peter Irving, Wladyslawa Czuber-Dochan

Crohns Colitis 360· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials.
Jean-Frédéric Colombel, Ana P Lacerda, Peter M Irving, Remo Panaccione, Walter Reinisch

Clin Gastroenterol Hepatol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis: A Retrospective, International Study.
Sailish Honap, Bénédicte Caron, Jacob E Ollech, Maya Fischman, Konstantinos Papamichael, Peter M Irving

Dig Dis Sci· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel Disease.
Hannah K Systrom, Victoria Rai, Siddharth Singh, Leonard Baidoo, Adam S Cheifetz, Peter M Irving

Am J Gastroenterol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of intestinal biopsy tissue preservation methods to facilitate large-scale mucosal microbiota research.
Nicola J Wyatt, Hannah Watson, Gregory R Young, Mary Doona, Ned Tilling, Peter M Irving

EBioMedicine· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis.
Séverine Vermeire, David T Rubin, Laurent Peyrin-Biroulet, Marla C Dubinsky, Miguel Regueiro, Peter M Irving

BMJ Open Gastroenterol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protocol for a first-in-human feasibility study of T regulatory cells (TR004) for inflammatory bowel disease using (ex vivo) Treg expansion (TRIBUTE).
Beverley Rodger, Jennifer Clough, Joana Vasconcelos, James B Canavan, D Macallan, Peter Irving

BMJ Open· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Bruce E Sands, Geert D'Haens, David B Clemow, Peter M Irving, Jordan T Johns

Inflamm Bowel Dis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An evaluation of mirikizumab for the treatment of ulcerative colitis.
Christopher White, Peter M Irving

Expert Opin Biol Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review.
Peter M Irving, Peter Hur, Raju Gautam, Xiang Guo, Severine Vermeire

J Manag Care Spec Pharm· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stem Cells and Stem Cell-Derived Factors for the Treatment of Inflammatory Bowel Disease with a Particular Focus on Perianal Fistulizing Disease: A Minireview on Future Perspectives.
Amy L Lightner, Peter M Irving, Graham M Lord, Aline Betancourt

BioDrugs· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Laurent Peyrin-Biroulet, J Casey Chapman, Jean-Frederic Colombel, Flavio Caprioli, Geert D'Haens, Peter M Irving

N Engl J Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
Neil Chanchlani, Simeng Lin, Claire Bewshea, Benjamin Hamilton, Amanda Thomas, Peter M Irving

Lancet Gastroenterol Hepatol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
Nurulamin M Noor, James C Lee, Simon Bond, Francis Dowling, Biljana Brezina, Peter M Irving

Lancet Gastroenterol Hepatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining predictors of responsiveness to advanced therapies in Crohn's disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine.
Nicola J Wyatt, Hannah Watson, Carl A Anderson, Nicholas A Kennedy, Tim Raine, Peter M Irving

BMJ Open· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis